Table 2.

Quizartinib treatment exposure and dose modifications (safety population)

	Quizartinib 30-mg group* (n = 38)	Quizartinib 60-mg group† (n = 36)‡	Total (N = 74)
Median duration of treatment (range), wk	9.4 (2.1-32.7)	10.1 (1.7-109)	10.0 (1.7-109)
Dose interrupted, n (%)	8 (21)	13 (36)	21 (28)
Dose reduced, n (%)	10 (26)	10 (28)	20 (27)
Dose escalated, n (%)	23 (61)	5 (14)	28 (38)

Quizartinib 30 mg and 60 mg are equivalent to 26.5 mg and 53 mg free base, respectively.

^*30-mg starting dose with permitted escalation to 60 mg for lack of or loss of initial response.

^†60-mg starting dose with permitted escalation to 90 mg for lack of or loss of initial response.

^‡Two patients were randomized but did not receive drug because of ineligibility.